Catalog No.
DHJ24004
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
Concentration
2.9 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8NBP7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
PF-04950615, RN-316, CAS: 1407495-02-6
Clone ID
Bococizumab
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients, PMID: 28304242
Bococizumab for the treatment of hypercholesterolaemia, PMID: 28060539
Bococizumab for the treatment of hypercholesterolaemia, PMID: 28552009
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies, PMID: 31529318
PCSK9 inhibition and inflammation: A narrative review, PMID: 31404822
PCSK9 inhibitors and cardiovascular outcomes, PMID: 31593483
Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects, PMID: 31549625
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials, PMID: 27502861
Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomized trial, PMID: 30623096
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab, PMID: 28304227
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab, PMID: 29685591
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways, PMID: 28886926
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia, PMID: 25784512
PCSK9 signaling pathways and their potential importance in clinical practice, PMID: 29209441
The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies, PMID: 29078037
Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study, PMID: 28539539
Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301], PMID: 28636184
Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development, PMID: 26382609
Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices, PMID: 29688615
Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin, PMID: 29057618
Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9 Inhibitor Studies, PMID: 31301293
A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development, PMID: 28181260
Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials, PMID: 29949039
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease, PMID: 28453187
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects, PMID: 29037448
The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials, PMID: 33417682
PCSK9 Monoclonal Antibodies: An Overview, PMID: 33014302
New Drugs for Lowering LDL-Cholesterol, PMID: 30044561
Treatment of Hypercholesterolemia in 2015, PMID: 26422823
Emerging biologic therapies for hypercholesterolaemia, PMID: 28617192
PCSK9 inhibitors - clinical applications, PMID: 27789928
Targeting PCSK9 for therapeutic gains, PMID: 25712137
Adding Insult to Injury: Are There Treatments for Myocardial Injury and Type 2 Myocardial Infarction?, PMID: 33372537
PCSK9 inhibition in patients with hypercholesterolemia, PMID: 25771732
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis, PMID: 31910414
Antibodies to watch in 2015, PMID: 25484055
LDL cholesterol, statins and PCSK 9 inhibitors, PMID: 26432726
PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia, PMID: 26886466
Efficacy and safety of PCSK9 monoclonal antibodies, PMID: 31623472
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update, PMID: 32939318
PCSK9 Inhibitors for Statin Intolerance?, PMID: 27039138
[Is lower better? Is lowest the best?], PMID: 28429686
Comments on the most important and recent studies involving PCSK9i, PMID: 30704247
Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy, PMID: 29716940
Promising new therapies for the treatment of hypercholesterolemia, PMID: 26822080
[PCSK9 inhibitors and dyslipidemias: an update on clinical evidence], PMID: 25002170
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes, PMID: 29095667
PCSK9 inhibitors--past, present and future, PMID: 26329686
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia, PMID: 27195910
Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9, PMID: 27389630
For research use only. Not for human or drug use.
